Biotechnology company Kallyope raised $21m in a funding round led by Microsoft founder Bill Gates to develop therapies based on the gut-brain axis. The firm is working with scientists at Stanford University and Massachusetts General Hospital (MGH) to test whether drugs that target specific regions of the gut can help treat conditions such as irritable bowel syndrome, Crohn@@ The company developed a platform centred on analysis of the bi-directional communication between the gut and the brain and said it had expanded its research to a series of programmes aimed at studying disorders of the metabolic, central nervous and gastrointestinal systems.
Biotechnology company Kallyope raised $21m in a funding round led by Microsoft founder Bill Gates to develop therapies based on the gut-brain axis. The backing was an extension to the firm’s series B funding round which had already raised $66m. The company developed a platform centred on analysis of the bi-directional communication between the gut and the brain and said it had expanded its research to a series of programmes aimed at studying disorders of the metabolic, central nervous and gastrointestinal systems.